menu
    • menu
    [{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Agence Nationale de la Recherche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"DT-7012","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Domain Therapeutics \/ Agence Nationale de la Recherche","highestDevelopmentStatusID":"4","companyTruncated":"Domain Therapeutics \/ Agence Nationale de la Recherche"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"5-Methyltetrazole","moa":"A2AR\/BR","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Domain Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"DT-9045","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-9081","moa":"||EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Domain Therapeutics","sponsor":"Panacea Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"DT-9081","moa":"EP4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Domain Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Domain Therapeutics \/ Panacea Venture","highestDevelopmentStatusID":"6","companyTruncated":"Domain Therapeutics \/ Panacea Venture"}]

    Find Clinical Drug Pipeline Developments & Deals by Domain Therapeutics

    Menu

    Domain Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-9045

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Domain Therapeutics to Present DT-9045 Data, a Novel Modulator for Immuno-oncology

                            Details : DT-9045 is a novel protease-activated receptor 2 (PAR2) negative allosteric modulator, small molecule drug candidate. It is being evaluated for the treatment of cancer.

                            Product Name : DT-9045

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 26, 2024

                            Lead Product(s) : DT-9045

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-7012

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Agence Nationale de la Recherche

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Domain Therapeutics Awarded Grant To Progress CCR8 Antibody Candidate

                            Details : A grant supports clinical progress of DT-7012, an anti-CCR8 monoclonal antibody, in preclinical studies for cutaneous T-cell lymphoma and other neoplasms.

                            Product Name : DT-7012

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : DT-7012

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Agence Nationale de la Recherche

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-9081

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Domain Therapeutics Announces First Patient Dosed With DT-9081 In Phase I Clinical Study In Patients With Adva...

                            Details : DT-9081 is an oral small molecule product which, by blocking the EP4 receptor present on immune cells, is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system.

                            Product Name : DT-9081

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 01, 2023

                            Lead Product(s) : DT-9081

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-9081

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Domain Therapeutics To Progress Into Clinical Trials With Its EP4R Antagonist DT-9081 In Solid Tumors

                            Details : DT-9081 is an oral small molecule drug candidate, which is able to reverse the prostaglandin E2 (PGE2)-mediated immunosuppression triggered by some tumors to bypass the immune system, by blocking the EP4 receptor present on immune cells.

                            Product Name : DT-9081

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 19, 2022

                            Lead Product(s) : DT-9081

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-9081

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Panacea Venture

                            Deal Size : $42.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Domain Therapeutics Raises $42m Series A Financing

                            Details : Domain Therapeutics will use the proceeds to i) conduct the clinical development of its EP4R antagonist, DT-9081, ii) advance two additional GPCR programs, and iii) progress its discovery-stage pipeline of a number of first-in-class assets targeting GPCR...

                            Product Name : DT-9081

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 05, 2022

                            Lead Product(s) : DT-9081

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Panacea Venture

                            Deal Size : $42.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 5-Methyltetrazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $261.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Domain Therapeutics Receives a Single Digit Multimillion Development Milestone Payment from Merck For M1069 Cl...

                            Details : A2a/A2b antagonist candidate, M1069, a first-in-human study to investigate the safety, tolerability, PK/PD and clinical activity in patients with metastatic or locally advanced unresectable solid tumors.

                            Product Name : M1069

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 28, 2022

                            Lead Product(s) : 5-Methyltetrazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : $261.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Domain Therapeutics

                            France arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DT-9081,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Domain Therapeutics To Present New Data On Its EP4R and CCR8 Antagonists at 2022 SITC Annual Meeting

                            Details : DT-9081 is a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models.

                            Product Name : DT-9081

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 10, 2022

                            Lead Product(s) : DT-9081,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth